The Case for Naming Sooner Rather Than Late

Drug companies are developing trademarks for new products at an earlier stage of development in an effort to entrench a brand in the minds of HCPs, BioJournalists, Potential Patients, Affinity Proponents, Academia and the Financial Community. The overwhelming majority of the professionals surveyed in the study stated that they develop generic and trademark names, 91% and 87% respectively, before or during Phase II of clinical trials.

The outcome of the study recommends seeking a trademark early — even during Phase I — as trademark searches have a low success rate. This fast movement is even more important for compounds with Expedited FDA Review Programs, Oncology, Orphan Drug, Cell and Gene Therapy Submissions.